Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 2,315
研究概览
简要总结
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating clinicopathological features and inflammatory signature to predict LR in LARC patients undergoing neoadjuvant therapy followed by total mesorectal excision.
详细描述
To address the gap in accessible and integrative risk prediction, this study aimed to develop and validate an interpretable machine learning model for the early prediction of postoperative local recurrence in LARC patients using a multicenter cohort. We employed SHapley Additive exPlanations (SHAP) analysis to elucidate feature importance and provide clear interpretations for individual predictions, with the ultimate goal of evaluating the model's clinical utility in guiding personalized patient management-particularly by identifying high-risk patients in clinical practice and informing tailored follow-up and treatment strategies to improve patient outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed cT>=3 or cN+ stage rectal cancer by pelvic MRI or enhanced CT scan;
- •Pathological proved primary rectal adenocarcinoma;
- •Recieved full-cource radiation or more than 3 cycles of chemotherapy before surgery;
- •Recieved radical tumor resection by TME surgery.
排除标准
- •Diganosed with any distant metastasis disease or locally unresectable disease before neoadjuvant treatment or surgery;
- •Recieved local resection surgery (R2 resection) or postoperative pathology confirmed positive surgical margins (R1 resection);
- •Patients who died due to intra- or post-operative complications;
- •Patient who die or relapse within 30 days after surgery;
- •Patients who had a prior history of malignancy within 5 years before surgery;
- •Patients who were loss of follow-up or had inadequate clinical data.
研究者
Cai Zerong
Deputy Director of the Department
Sixth Affiliated Hospital, Sun Yat-sen University